Esophagus

Esophagus is the official journal of the Japan Esophageal Society, published by Springer Japan and founded in 2003, and it deals with benign and malignant disease of the esophagus, with a 2025 Journal Impact Factor of 5.8.《食管》（Esophagus）是日本食管学会的官方期刊，由（Springer Japan）出版，2003 年创刊，刊载食管良性与恶性疾病研究，2025 年期刊影响因子为 5.8。

Scope

• Benign and malignant esophageal disease is the shared subject, from gastroesophageal reflux and motility disorders to squamous cell carcinoma and adenocarcinoma.食管良性与恶性疾病是共同主题，涵盖胃食管反流、动力障碍，直到鳞状细胞癌与腺癌。
• Original articles report clinical and translational research on diagnosis, surgical technique, endoscopy and perioperative management.原创论文报告诊断、手术技术、内镜与围手术期管理方面的临床与转化研究。
• Review articles summarise the state of the art on defined clinical questions, often commissioned by the editorial board.综述文章就特定临床问题总结最新进展，多由编委会约稿。
• Technical notes under the heading How I do it describe operative and endoscopic technique in a short, practical format and are a signature of the journal.以（How I do it）为栏目的技术札记，以简短实用的形式描述手术与内镜技巧，是本刊的标志性内容。
• Letters to the editor are encouraged as a forum, and the board contributes invited special articles on esophageal disease.期刊鼓励读者来信以形成讨论园地，编委会亦提供约稿的食管疾病专题文章。
• Proceedings of symposia and workshops from the annual congress of the society are published as special issues.学会年会期间研讨会与工作坊的论文集，以专刊形式出版。
• Work that crosses surgery, gastroenterology, medical oncology, radiation oncology and pathology is welcome, reflecting the multidisciplinary care of esophageal cancer.横跨外科、消化内科、肿瘤内科、放射肿瘤与病理学的研究均受欢迎，呼应食管癌的多学科诊疗。

History

• The Japan Esophageal Society established the title as its English-language organ, and the first issue is dated 2003.日本食管学会创办本刊作为其英文会刊，首期标注为 2003 年。
• It is published from Tokyo by Springer Japan and appears four times a year in a single annual volume.期刊由（Springer Japan）在东京出版，每年四期、一卷。
• Publication follows a hybrid model, so individual articles may be opened on payment of an article processing charge while subscription content remains.出版采用混合模式，单篇论文可支付文章处理费后开放获取，订阅内容同时保留。
• The journal is indexed in MEDLINE, Science Citation Index Expanded, Scopus and Embase, among other databases.本刊被 MEDLINE、科学引文索引扩展版、Scopus 与 Embase 等数据库收录。
• The 2025 Journal Impact Factor is 5.8, against 3.8 in 2024, 3.671 in 2022 and 4.23 in 2021.2025 年期刊影响因子为 5.8，2024 年为 3.8，2022 年为 3.671，2021 年为 4.23。
• In the 2025 Journal Citation Reports it ranks 28th of 153 titles in gastroenterology and hepatology, in the first quartile.在 2025 年期刊引证报告中，本刊于胃肠病学与肝病学类 153 种期刊中位列第 28，属第一四分位。

Editors

• Yuichiro Doki of Osaka University is editor-in-chief. His own work is on esophageal surgery and multimodal treatment of esophageal cancer.大阪大学的 Yuichiro Doki 任主编，其研究集中于食管外科与食管癌的多模式治疗。
• Hideaki Shimada of Toho University Omori Medical Center is deputy editor-in-chief.东邦大学大森医疗中心的 Hideaki Shimada 任副主编。
• Kouhei Akazawa of Niigata University Medical and Dental Hospital and Satoshi Hattori of Osaka University serve as statistical consultants and review the quantitative content of submitted papers.新潟大学医齿学综合医院的 Kouhei Akazawa 与大阪大学的 Satoshi Hattori 担任统计顾问，负责审读投稿中的定量分析。
• Roughly two dozen associate editors, all at Japanese institutions, cover surgery, endoscopy, medical oncology, radiation oncology and pathology, among them Hiroya Takeuchi at Hamamatsu, Ryu Ishihara at the Osaka International Cancer Institute and Keiichi Jingu at Tohoku University.约二十余名副编辑全部来自日本机构，覆盖外科、内镜、肿瘤内科、放射肿瘤与病理，其中包括滨松医科大学的 Hiroya Takeuchi、大阪国际癌症研究所的 Ryu Ishihara 与东北大学的 Keiichi Jingu。
• Manuscripts are peer reviewed by the editorial board, and the median time to first decision is nine days.稿件由编委会组织同行评审，初审中位时间为 9 天。
• The board commissions the special articles and assembles the congress proceedings, which gives the journal a strongly society-driven editorial agenda.编委会负责约组专题文章并汇编年会论文集，使期刊的编辑议程带有鲜明的学会主导色彩。